GSK's Tafenoquine Faces Questions Over Review Pathways At US FDA Panel
Executive Summary
Advisory committee questions about malaria drug’s breakthrough therapy and orphan drug designations reflect lingering confusion about how agency’s various regulatory pathways impact product development and approval.